A study out of Scotland has linked levels of 2 short-chain fatty acids in female patients with early-stage breast cancer to pathological complete response (pCR) to neoadjuvant chemotherapy.
A study out of Scotland, to be presented at this year’s virtual European Breast Cancer Conference in October, has linked levels of 2 short-chain fatty acids (SCFAs) in female patients with early-stage breast cancer to pathological complete response (pCR) to neoadjuvant chemotherapy (NACT), according to the abstract released today.
The 2 SCFAs are propionate and butyrate, and they were shown to be lower in the gut bacteria of patients achieving pCR compared with those not achieving pCR after surgery.
“In this study we have started to look at whether the function of the gut microbiome could be one factor that influences the effectiveness of chemotherapy,” said Kirsty Ross, MBChB, MSc, a specialist registrar in medical oncology at the Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Ross and her fellow authors also noted that the 2 SCFAs they investigated are known to “dampen down the immune system’s ability to target cancer cells,” but they haven’t been looked at in the present study’s setting. To determine the levels of propionate and butyrate, the investigators examined the study group’s stool samples using gas chromatography at 3 time points: before first NACT (T1), at NACT mid point (T2), and after the final NACT cycle (T3). The healthy group was sampled just once. pCR was evaluated through tissue samples following surgery.
The study population comprised 2 cohorts. The 21 patients in the study group had early-stage breast cancer and were being treated at Beatson West of Scotland Cancer Centre. Their median age and BMI were 56 (range, 33-72) years and 28.6 kg/m2 (range, 19.6-55.6 kg/m2), respectively. In the healthy control group, there were 24 women, with a median age of 46 (range, 31-61) years and BMI of 25.9 mg/m2 (range, 18.0-42.4 kg/m2).
Overall, pCR was seen in 25% of evaluable patients, and there were no significant differences in SCFA levels for the health controls and study patients at T1.
However, significantly lower mean concentrations (μmol/g) were seen at T3 for propionate and butyrate between the patients who achieved pCR and those who did not:
Results were available for 20 participants in each cohort. In the study group, 42.9% had human epidermal growth factor receptor 2 (HER2)-positive disease, 38.1% had triple-negative disease, and 19% had estrogen receptor-positive, HER2-negative disease. Their treatments consisted of FEC-T (42.9%), FEC-TH (28.6%), and other (28.6%).
“We speculate that lower proprionate and butyrate concentrations may result in a relatively lower peripheral Treg proportion, which in turn supports development of a more immune-stimulatory tumour microenvironment and improved pCR,” the investigators concluded. “Further investigation is warranted including immunophenotyping of patients peripheral blood and tumour-infiltrating lymphocytes.”
They hope their results lead to additional investigations of how to increase chemotherapy’s effectiveness, and they are planning larger studies on the influence of gut microbiota in breast cancer subtypes and on anticancer immune responses.
Reference
Ross K. Gut microbial short chain fatty acids are associated with pathological complete response (pCR) after neoadjuvant chemotherapy for breast cancer. Presented at: 12th European Breast Cancer Conference; October 2-3, 2020. Abstract 105.
Metabolic Syndrome, Obesity Contribute to Breast Cancer Mortality in Postmenopausal Women
May 13th 2024A large study finds that obesity and metabolic syndrome raise breast cancer mortality risk, but through different mechanisms. Metabolic syndrome is linked to a specific type of breast cancer, whereas obesity increases risk across all breast cancer subtypes.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Social Equity, Strong Health Care Systems Can Improve Advanced Breast Cancer Outcomes Globally
May 6th 2024Disparities in health care systems around the world limit access to effective treatments for advanced breast cancer, especially for people in low- and middle-income countries and marginalized communities. Stronger health systems and social education efforts are necessary to improve outcomes for all patients.
Read More
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More